Anti-FAM13A monoclonal antibody

Pre-made anti-FAM13A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to FAM13A/FAM13A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2485-Ab-1/ GM-Tg-hg-IP2485-Ab-2Anti-Human FAM13A monoclonal antibodyHuman
GM-Tg-rg-IP2485-Ab-1/ GM-Tg-rg-IP2485-Ab-2Anti-Rat FAM13A monoclonal antibodyRat
GM-Tg-mg-IP2485-Ab-1/ GM-Tg-mg-IP2485-Ab-2Anti-Mouse FAM13A monoclonal antibodyMouse
GM-Tg-cynog-IP2485-Ab-1/ GM-Tg-cynog-IP2485-Ab-2Anti-Cynomolgus/ Rhesus macaque FAM13A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2485-Ab-1/ GM-Tg-felg-IP2485-Ab-2Anti-Feline FAM13A monoclonal antibodyFeline
GM-Tg-cang-IP2485-Ab-1/ GM-Tg-cang-IP2485-Ab-2Anti-Canine FAM13A monoclonal antibodyCanine
GM-Tg-bovg-IP2485-Ab-1/ GM-Tg-bovg-IP2485-Ab-2Anti-Bovine FAM13A monoclonal antibodyBovine
GM-Tg-equg-IP2485-Ab-1/ GM-Tg-equg-IP2485-Ab-2Anti-Equine FAM13A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2485-Ab-1/ GM-Tg-hg-IP2485-Ab-2; GM-Tg-rg-IP2485-Ab-1/ GM-Tg-rg-IP2485-Ab-2;
GM-Tg-mg-IP2485-Ab-1/ GM-Tg-mg-IP2485-Ab-2; GM-Tg-cynog-IP2485-Ab-1/ GM-Tg-cynog-IP2485-Ab-2;
GM-Tg-felg-IP2485-Ab-1/ GM-Tg-felg-IP2485-Ab-2; GM-Tg-cang-IP2485-Ab-1/ GM-Tg-cang-IP2485-Ab-2;
GM-Tg-bovg-IP2485-Ab-1/ GM-Tg-bovg-IP2485-Ab-2; GM-Tg-equg-IP2485-Ab-1/ GM-Tg-equg-IP2485-Ab-2
Products NameAnti-FAM13A monoclonal antibody
Formatmab
Target NameFAM13A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-FAM13A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2485-Ag-1Recombinant multi-species FA13A/ FAM13A/ ARHGAP481 protein
    ORF Viral VectorpGMLPm003882mouse Fam13a Lentivirus plasmid
    ORF Viral VectorvGMLPm003882mouse Fam13a Lentivirus particle


    Target information

    Target IDGM-IP2485
    Target NameFAM13A
    Gene ID10144,58909,362378,703335,487854,101092604,282605,100063998
    Gene Symbol and SynonymsARHGAP48,D430015B01Rik,FAM13A,FAM13A1,Precm1,RGD1309807
    Uniprot AccessionO94988,Q8HYW0
    Uniprot Entry NameFA13A_HUMAN,FA13A_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000138640
    Target ClassificationN/A

    The target: FAM13A, gene name: FAM13A, also named as ARHGAP481, FAM13A. Predicted to enable GTPase activator activity. Predicted to be involved in regulation of small GTPase mediated signal transduction. Predicted to be located in cytosol. Implicated in chronic obstructive pulmonary disease. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.